Skip to content

Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in High-Grade Lymphoma Across the UKCHART Network

DECIPHER - Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in High-Grade Lymphoma Across the UKCHART Network

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07813585
Acronym
DECIPHER
Enrollment
2000
Registered
2026-09-10
Start date
2026-10-01
Completion date
2027-09-01
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

DECIPHER is a retrospective multicentre observational cohort study using data collected across UKCHART sites. The study will evaluate the impact of ethnicity, socioeconomic deprivation and comorbidity burden on treatment delivery and outcomes in adults diagnosed with DLBCL between 2021 and 2025.

Detailed description

Despite the provision of universal healthcare through the National Health Service (NHS), variation in treatment delivery and outcomes among patients with diffuse large B-cell lymphoma (DLBCL) persists. Previous UK population-based studies have demonstrated that socioeconomic factors and multimorbidity influence survival outcomes in aggressive lymphoma, with patients from more deprived backgrounds experiencing poorer outcomes than those from less deprived areas. Furthermore, multimorbidity has been associated with diagnostic delay and emergency presentation, factors known to adversely affect lymphoma outcomes. National datasets such as the National Cancer Registration and Analysis Service (NCRAS) and the Systemic Anti-Cancer Therapy (SACT) database provide valuable population-level real-world evidence and have improved understanding of lymphoma outcomes at a national level. However, these datasets often lack the detailed clinical information required to fully explore the impact of ethnicity, socioeconomic deprivation, frailty, comorbidity burden, treatment modifications, and treatment delivery on patient outcomes. The UK Consortium for Haematology Audit, Real-world Data and Trials (UKCHART) provides a unique opportunity to address these evidence gaps. Through a network of participating NHS organisations serving a large, diverse, and geographically distributed population, UKCHART enables the collection of detailed patient-level clinical data that are not routinely available within national registries. The demographic diversity of the UKCHART population makes it particularly well suited to investigating healthcare inequalities and understanding how ethnicity, deprivation, and comorbidity influence treatment delivery and outcomes in patients with DLBCL. This study will utilise the UKCHART network to evaluate the impact of ethnicity, socioeconomic deprivation, and comorbidity burden on the delivery of frontline chemoimmunotherapy and subsequent clinical outcomes in patients with newly diagnosed DLBCL. By generating contemporary UK real-world evidence, the study aims to identify potentially modifiable factors contributing to outcome disparities and inform future strategies to improve equity of care for patients with high-grade lymphoma.

Interventions

None listed

Sponsors

The Royal Wolverhampton Hospitals NHS Trust
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adults aged ≥18 years. * Newly diagnosed DLBCL. * Managed within participating UKCHART sites.

Exclusion criteria

* Transformed lymphoma. * Insufficient linkage data.

Design outcomes

Primary

MeasureTime frameDescription
Treatment completionTime Period between 2021-2026Delivered versus planned number of frontline chemoimmunotherapy cycles
Dose intensity reductionTime Period between 2021-2026Occurrence and magnitude (%) of chemotherapy dose reductions, particularly reductions \>25% from planned treatment

Secondary

MeasureTime frameDescription
Overall Survival (OS)Time Period between 2021-2026Measured as time from diagnosis (or treatment start, as defined in the SAP) to death from any cause
Progression-Free Survival (PFS)Time Period between 2021-2026Measured as time from diagnosis/treatment initiation to disease progression, relapse, or death.
Stage at DiagnosisTime Period between 2021-2026Measured using Ann Arbor stage recorded at diagnosis
Time to Treatment InitiationTime Period between 2021-2026Measured as the interval between diagnosis and commencement of first-line treatment.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026